Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/46910
Title: Highly active ozonides selected against drug resistant malaria
Authors: Lobo, Lis 
Sousa, Bruno de 
Cabral, Lília 
Cristiano, Maria LS 
Nogueira, Fátima 
Keywords: Animals; Antimalarials; Artemisinins; Chloroquine; Disease Models, Animal; Female; Humans; Malaria, Falciparum; Mefloquine; Mice; Parasitemia; Plasmodium falciparum
Issue Date: 2016
Serial title, monograph or event: Memórias do Instituto Oswaldo Cruz
Volume: 111
Issue: 7
Abstract: Ever increasing multi-drug resistance by Plasmodium falciparum is creating new challenges in malaria chemotherapy. In the absence of licensed vaccines, treatment and prevention of malaria is heavily dependent on drugs. Potency, range of activity, safety, low cost and ease of administration are crucial issues in the design and formulation of antimalarials. We have tested three synthetic ozonides NAC89, LC50 and LCD67 in vitro and in vivo against multidrug resistant Plasmodium. In vitro, LC50 was at least 10 times more efficient inhibiting P. falciparum multidrug resistant Dd2 strain than chloroquine and mefloquine and as efficient as artemisinin (ART), artesunate and dihydroartemisinin. All three ozonides showed high efficacy in clearing parasitaemia in mice, caused by multi-drug resistant Plasmodium chabaudi strains, by subcutaneous administration, demonstrating high efficacy in vivo against ART and artesunate resistant parasites.
URI: http://hdl.handle.net/10316/46910
DOI: 10.1590/0074-02760160077
Rights: openAccess
Appears in Collections:I&D CINEICC - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
2016_Lobo_et_at.pdf229.46 kBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

1
checked on Feb 18, 2020

WEB OF SCIENCETM
Citations

1
checked on May 29, 2020

Page view(s)

279
checked on Jul 9, 2020

Download(s)

83
checked on Jul 9, 2020

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.